The state of the National Health Service is always a major issue come election time, and the run-up to the UK’s 12 December poll this year is unlikely to be an exception.
The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs.
A move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on public health is shaking the healthcare system to its core.